Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Hypertrophic cardiomyopathy: screening and management in childhood

    Dear Editor

    Optimal age for screening for familial HCM.

    McKenna and Behr´s recommendation that offspring of carriers of mutations causing hypertrophic cardiomyopathy (HCM) should have regular evaluation “during puberty and early adulthood” could be read as suggesting that evaluation for carrier status is not necessary before puberty. This would be a pity as there is now good evidence arguing for echo...

    Show More
    Conflict of Interest:
    None declared.